Acetazolamide (often known by the brand name Diamox®) is the most common medication used to treat idiopathic intracranial hypertension (IIH).
While it is often referred to as a "water pill" (diuretic), in the context of IIH, its primary job is to decrease the production of cerebrospinal fluid (CSF) inside the brain. By reducing the amount of fluid produced, it helps lower the pressure inside the skull, protecting the optic nerves and reducing headaches.
We recognize that while acetazolamide is highly effective, it can be a difficult medication to start. Many patients experience side effects early on that lead them to stop treatment before the benefits are realized.
The Ottawa Headache Centre's acetazolamide protocol focuses on:
Gradual titration: Starting with a low dose and increasing slowly to allow your body to adjust.
Side effect management: Providing proactive strategies to minimize discomfort.
Vision-first monitoring: Using the medication as a tool to stabilize your vision.
Acetazolamide is typically started at a low dose (e.g., 250 mg or 500 mg daily) and increased gradually. The speed of how quickly to increase dose is individualized to each person: some people require rapid increase over days to preserve vision, for others we increase it more slowly over weeks.
The medication works best when a steady level is maintained in your bloodstream. It should be taken at the same time(s) each day.
Do not stop abruptly.
If you are having trouble with the medication, contact our clinic or your pharmacist before stopping. A gradual "taper" is often preferred.
Most side effects of acetazolamide are dose-related and often improve as your body habituates to the medication.
The most common side effect is a "pins and needles" sensation in the fingers, toes, or around the mouth.
Tip: This is often related to how the medication affects electrolytes. Some patients find that increasing potassium-rich foods (like bananas, oranges, or potatoes) can help.
Acetazolamide can make carbonated beverages (soda, sparkling water, beer) taste metallic or "flat."
Tip: This is a direct effect of the medication on an enzyme in your taste buds. If this occurs, it is best to avoid carbonated drinks until the dose is adjusted or the treatment is completed.
Some patients feel tired or less mentally sharp when starting the medication.
Tip: Taking the largest portion of your dose in the evening can sometimes help mitigate daytime sleepiness.
As a diuretic, you will likely need to use the bathroom more frequently.
Tip: Stay well-hydrated with water, but try to limit fluid intake 2 hours before bed to improve sleep quality.
If you have been diagnosed with IIH — or are being investigated for it — early specialist involvement is important.
Seek urgent medical attention if you experience:
Sudden vision loss
Rapid worsening of visual fields
Severe new neurological symptoms
Persistent double vision
Vision changes should always be taken seriously. Protecting vision and stabilizing headache outcomes requires coordinated care.
Early evaluation can prevent long-term complications.
If you think your headache may be more than chronic migraine, ask your doctor for a referral to the Ottawa Headache Centre.
Acetazolamide works by:
Reducing CSF production in the brain
Lowering intracranial pressure over time
Helping protect the optic nerves and vision
It does not directly treat pain, but by lowering pressure it can improve pressure-related symptoms and reduce the risk of vision loss.
Many people experience some side effects, especially early on.
Common effects include:
Tingling in fingers, toes, or around the mouth
Fatigue or low energy
Increased urination
Altered taste (especially carbonated drinks)
Nausea or stomach upset
These effects are often dose-related and may improve with time or dose adjustment.
Less common side effects can include:
Electrolyte imbalances
Kidney stones
Low potassium levels
This material is provided for educational purposes and does not replace independent clinical judgment or institutional protocols. Management decisions remain the responsibility of the treating clinician.